Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability

International Journal of Pharmaceutics

Volumn 394, Issue 1-2, 2010, Pages 179-185

  Zhuang, Chun Yang ^a   Li, Ning ^a   Wang, Mi ^a   Zhang, Xiao Ning ^b   Pan, Wei San ^a   Peng, Jun Jie ^a   Pan, Yu Sheng ^a   Tang, Xin ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Tsinghua University   (China)

Author keywords

Nanostructure lipid carriers; Oral bioavailability; Poorly water soluble drugs; Sustained release; Vinpocetine

Indexed keywords

GLYCEROL STEARATE; MIGLYOL; PHOSPHATIDYLCHOLINE; POLOXAMER; SOLUTOL HS 15; VINPOCETINE; DELAYED RELEASE FORMULATION; DRUG CARRIER; LIPID; NANOPARTICLE; NOOTROPIC AGENT; VINCA ALKALOID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; WISTAR RAT; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; MALE; ORAL DRUG ADMINISTRATION; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; LIPIDS; MALE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NOOTROPIC AGENTS; RATS; RATS, WISTAR; SOLUBILITY; VINCA ALKALOIDS; X-RAY DIFFRACTION;

EID: 77953689484     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.05.005     Document Type: Article

References (31)

1. Bönöczk P., Gulyás B., Adam-Vizi V., Nemes A., Kárpáti E., Kiss B., Kapás M., Szántay C., Koncz I., Zelles T., Vas A. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 2000, 53:245-254.
2. Buszello K., Harnisch S., Müller R.H., Müller B.W. The influence of alkali fatty acids on the properties and the stability of parenteral O/W emulsions modified with Solutol HS 15. Eur. J. Pharm. Biopharm. 2000, 49:143-149.
3. Cavalli R., Caputo O., Marengo E., Pattarino F., Gasco M.R. The effect of the components of microemulsions on both size and crystalline structure of solid lipid nanoparticles (SLN) containing a series of model molecules. Pharmazie 1998, 53:392-396.
4. Chen Y., Li G., Wu X., Chen Z., Hang J., Qin B., Chen S., Wang R. Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. Biol. Pharm. Bull. 2008, 31:118-125.
5. Chiu P.J., Tetzloff G., Ahn H.S., Sybertz E.J. Comparative effects of vinpocetine and 8-Br-cyclic GMP on the contraction and 45Ca-fluxes in the rabbit aorta. Am. J. Hypertens. 1988, 1:262-268.
6. Elbary A., Foda N., El-Gazayerly O., Khatib M.E. Reversed phase liquid chromatographic determination of vinpocetine in human plasma and its pharmacokinetic application. Anal. Lett. 2002, 35:1041-1054.
7. García-Fuentes M., Torres D., Alonso M.J. Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf. B Biointerfaces 2002, 27:159-168.
8. Hu F.Q., Jiang S.P., Du Y.Z., Yuan H., Ye Y.Q., Zeng S. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf. B Biointerfaces 2005, 45:167-173.
9. Jacobs C., Kayser O., Müller R.H. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int. J. Pharm. 2000, 196:161-164.
10. Labouret A., Thioune O., Fessi H., Devissaguet J.P., Puisieux F. Application of an original process for obtaining colloidal dispersions of some coating polymers. Preparation, characterization, industrial scale-up. Drug Dev. Ind. Pharm. 1995, 21:229-241.
11. Levy M.Y., Benita S. Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int. J. Pharm. 1990, 66:29-37.
12. Lindmark T., Nikkila T., Artursson P. Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 1995, 275:958-964.
13. Miskolczi P., Korma K., Polgár M., Vereczkey L. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur. J. Drug Metab. Pharmacokinet. 1990, 15:1-5.
14. Mohamed A.A.M., Sayed H.K., Mohsen A.B., Abdulaziz A.A.A. Oral administration of liposomes containing cyclosporine: a pharmacokinetic study. Int. J. Pharm. 1998, 168:163-168.
15. Morazzoni P., Montalbetti A., Malandrino S., Pifferi G. Comparative pharmacokinetics of silipide and silymarin in rats. Eur. J. Drug Metab. Pharmacokinet. 1993, 18:289-297.
16. Mühlen A.Z., Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles. Pharmazie 1998, 53:552-564.
17. Mühlen A.Z., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 1998, 45:149-155.
18. Müller R.H., et al. Solid nanoparticle (SLN) and nanostructured lipid carrier (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54:131-155.
19. O'Driscoll C.M., Griffin B.T. Biopharmaceutical challenges associated with drugs with low aqueous solubility-the potential impact of lipid-based formulations. Adv. Drug Deliv. Rev. 2008, 60:617-624.
20. Paliwal R., Rai S., Vaidya B., Khatri K., Goyal A.K., Mishra N., Mehta A., Vyas S.P. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 2009, 5:184-191.
21. Plain K.J., Wilson C.G. The effect of different oils on the absorption of probucol in the rat. J. Pharm. Pharmacol. 1984, 36:641-643.
22. Polgár M., Vereczkey L., Nyáry I. Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion. J. Pharm. Biomed. Anal. 1985, 3:131-139.
23. Reinhart T., Bauer K.H. The hemolysis and solubilization behavior of nonionic polymer surface-active agents classes. Pharmazie 1995, 50:407-408.
24. Ritger P.L., Peppas N.A. A simple equation for description of solute release. I. Fickian and non-Fickian release from nonswellable device in the form of slabs, spheres, cylinders or discs. J. Control. Release 1987, 5:23-26.
25. Ruchatz F., Schuch H. Physicochemical properties of Solutol HS 15 and its solubisates. BASF ExAct 1998, 1:6-7.
26. Shah N.H., Carvajal M.T., Patel C.I., Infeld M.H., Malick A.W. Self-emulsifying drug delivery systems (SEDDS) with polyglycolysed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharm. 1994, 106:15-23.
27. Szakács T., Veres Z., Vereczkey L. In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. Pol. J. Pharmacol. 2001, 53:623-628.
28. Trotta M., Debernardi F., Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int. J. Pharm. 2003, 257:153-160.
29. Volkhard J., Andreas F.T., Sven H.G. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 2000, 199:167-177.
30. Washington C. Drug release from microdisperse systems: a critical review. Int. J. Pharm. 1990, 58:1-12.
31. Yang S., Zhu J., Lu Y., Liang B., Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 1999, 16:751-757.